Stay updated with breaking news from Nasdaq Srpt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Royal Bank of Canada reissued their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research note published on Tuesday, Benzinga reports. The brokerage currently has a $148.00 price target on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the stock. Needham & Company […]
Wedbush began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $224.00 target price on the biotechnology company’s stock. Wedbush also issued estimates for Sarepta Therapeutics’ Q4 2023 earnings at $0.04 EPS, FY2023 earnings […]
Acadian Asset Management LLC reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 49.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 498 shares of the biotechnology company’s stock after selling 494 shares during the period. Acadian Asset Management LLC’s holdings in Sarepta Therapeutics were worth $57,000 […]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) saw unusually-strong trading volume on Wednesday after the company announced better than expected quarterly earnings. Approximately 889,703 shares changed hands during mid-day trading, a decline of 35% from the previous session’s volume of 1,360,735 shares.The stock last traded at $70.02 and had previously closed at $67.31. The […]
First Horizon Advisors Inc. increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 308.3% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 245 shares of the biotechnology company’s stock after purchasing an additional 185 shares during the period. First Horizon Advisors Inc.’s holdings in Sarepta Therapeutics were […]